Fresenius Medical Care AG & Co. KGaA (ETR:FME) Receives €75.00 Price Target Within UBS Group

0

Fresenius Medical Care AG & Co. KGaA (ETR: FMEGet a rating) received a €75.00 ($78.95) price target from UBS Group equity research analysts in a research note released Wednesday, Borsen Zeitung reports. UBS Group’s price target suggests upside potential of 28.38% from the company’s current price.

Other analysts have also recently published research reports on the company. Deutsche Bank Aktiengesellschaft set a price target of €58.00 ($61.05) on Fresenius Medical Care AG & Co. KGaA in a Tuesday, March 22 research note. Credit Suisse Group set a €61.00 ($64.21) price target on Fresenius Medical Care AG & Co. KGaA in a Thursday, May 5 research report. Stifel Nicolaus set a price target of €60.00 ($63.16) on Fresenius Medical Care AG & Co. KGaA in a Friday, February 4 report. Jefferies Financial Group set a price target of €53.00 ($55.79) on Fresenius Medical Care AG & Co. KGaA in a Tuesday, February 22 report. Finally, Berenberg Bank set a price target of €83.40 ($87.79) on Fresenius Medical Care AG & Co. KGaA in a Thursday, May 5 report.

Shares of ETR FME opened at €58.42 ($61.49) on Wednesday. The 50-day moving average share price is €59.83 and its 200-day moving average price is €58.51. Fresenius Medical Care AG & Co. KGaA has a 52-week minimum of €50.98 ($53.66) and a 52-week maximum of €71.14 ($74.88). The stock has a market capitalization of $17.12 billion and a P/E ratio of 17.65. The company has a quick ratio of 0.76, a current ratio of 1.10 and a debt ratio of 95.29.

Fresenius Medical Care AG & Co. KGaA Company Profile (Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

See also



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.